References
- Pratt G. Molecular aspects of multiple myeloma. J Clin Pathol: Mol Pathol 2002; 55: 273–283
- Reed J C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541–546
- Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006; 43: 1–67
- Pettersson M, Jernberg-Wiklund H, Larsson L-G, Sundstrom C, Givol I, Tsujimoto Y, et al. Expression of the bcl-2 gene in human myeloma cell lines and normal plasma cells. Blood 1992; 79: 495–502
- Reed J C. Dysregulation of apoptosis in cancer. J Clin Oncol 1999; 17: 2941–2953
- Klasa R J, Gillum A M, Klem R E, Frankel S R. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002; 12: 193–213
- Tian E, Hu W-X, Gazitt Y. Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines: a study with inducible bcl-2 transfection constructs. Int J Oncol 1996; 9: 165–169
- Hu W-X, Gazitt Y. Bcl-2 plays a major role in resistance to dexamethasone induced apoptosis in multiple myeloma cell lines. Int J Oncol 1996; 9: 375–381
- Gazitt Y, Fey V, Thomas C, Alvarez R. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. Int J Oncol 1998; 13: 397–405
- Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel D S. Role of NF-κB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by Bcl-2. Blood 1999; 93: 3044–3052
- Iyer R, Ding L M, Batchu R B, Naugler S, Shammas M A, Munshi N C. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. Leuk Res 2003; 27: 73–78
- Gazitt Y, Rothenberg M L, Hilsenbeck S G, Fey V, Thomas C, Montgomrey W. Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998; 13: 839–848
- Chanan-Khan A, Czuczman M S. Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Curr Treat Options Oncol 2004; 5: 261–267
- Van de Donk N WCJ, Kamphuis M MJ, Van Dijk M, Borst H PE, Bloem A C, Lokhorst H M. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003; 17: 211–219
- Proposed guidelines for protocol studies. II. Plasma cell myeloma. Prepared by a committee of the chronic leukemia – myeloma task force, National Cancer Institute. Cancer Chemother Rep 3 1968; 1: 17–39
- Bladé J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123
- Badros A Z, Goloubeva O, Rapoport A P, Ratterree B, Gahres N, Meisenberg B, et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005; 23: 4089–4099
- Van de Donk N W, de Weerdt O, Veth G, Eurelings M, van Stralen E, Frankel S R, et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 2004; 18: 1078–1084
- Weber D M, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E A, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142
- Dimopoulos M, Spencer A, Attal M, Prince H M, Harousseau J L, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132
- O'Brien S, Moore J O, Boyd T E, Larratt L M, Skotnicki A, Koziner B, et al. Randomized Phase 3 trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114–1120
- O'Brien S M, Cunningham C C, Golenkov A K, Turkina A G, Novick S C, Rai K R. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oliogonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 7697–7702
- O'Connor O A, Smith E A, Toner L E, Teruya-Feldstein J, Frankel S, Rolfe M, et al. The combination of the proteasome inhibitor Bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide. Clin Cancer Res 2006; 12: 2902–2911